A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of the Efficacy and Safety of Treating Acute Tonsillitis With Reyanning Mixture Alone/in Combination With Antibiotics.
Overview
- Phase
- Phase 4
- Intervention
- Reyanning mixture
- Conditions
- Acute Tonsillitis
- Sponsor
- China Academy of Chinese Medical Sciences
- Enrollment
- 144
- Primary Endpoint
- recovery time
- Last Updated
- 7 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of treating with acute tonsillitis using Reyanning mixture alone/in combination with antibiotics, and its function of reducing the use of antibiotics.
Detailed Description
In order to evaluate the efficacy,safety and the function of reducing the use of antibiotics of Reyanning mixture (a mixture of Chinese herbal medicine) in treating with acute tonsillitis, a randomized, double-blind, placebo-controlled, multicenter clinical trials will be established. According to the relevant regulations of the China Food and Drug Administration(CFDA), 144 cases need to be registered at least. The aim population is who suffering of acute tonsillitis from October 2018 to December 2019.These cases will be randomly divided into treatment group 1(Reyanning mixture +amoxil capsule simulator),treatment group 2(Reyanning mixture +amoxil capsule) and control group(Reyanning mixture simulator +amoxil capsule).Each group will be treated for 7 days and followed up for 3 times . The main indicators include the recovery time/rate and antibiotic duration/dosage. And the vanish rate of single symptom/physical sign, the ratio of white blood cell count(WBC) recovery, the time of fever will be observed as well.
Investigators
Yanming Xie
Deputy director
China Academy of Chinese Medical Sciences
Eligibility Criteria
Inclusion Criteria
- •Meet the diagnostic criteria of acute tonsillitis;
- •Meet the traditional Chinese medicine symptom diagnostic criteria of external wind-heat type and excessive heat in the lung and stomach type;
- •18 years≤age≤65 years;
- •course of disease within 72 hours;
- •sign informed consent.
Exclusion Criteria
- •common cold,influenza, acute laryngopharyngitis, pharyngeal diphtheria, wensang's isthmitis.
- •complicated with acute tracheobronchitis,pneumonia,rheumatic fever, acute glomerulonephritis or rheumatic heart disease.
- •complicated with severe angiocardiopathy, cerebrovascular disease, hemopoietic system disease or psychopath.
- •liver or kidney function is abnormal(ALT\>1.5 times upper limit of normal; Cr\>upper limit of normal); diabetic.
- •WBC\<10×109/L and neutrophilic granulocyte percentage\<75%;or WBC ≥20×109/L;
- •gestational, lactating women or who planning to get pregnant within half a year.
- •already accept similar traditional Chinese medicine or antibiotic within 48 hours before registered.
- •joining other clinical trials or allergic to any drug in this trials.
Arms & Interventions
treatment group 1
Reyanning mixture+amoxil capsule simulator
Intervention: Reyanning mixture
treatment group 1
Reyanning mixture+amoxil capsule simulator
Intervention: amoxil capsule simulator
treatment group 2
Reyanning mixture +amoxil capsule
Intervention: Reyanning mixture
treatment group 2
Reyanning mixture +amoxil capsule
Intervention: amoxil capsule
control group
Reyanning mixture simulator +amoxil capsule
Intervention: amoxil capsule
control group
Reyanning mixture simulator +amoxil capsule
Intervention: Reyanning mixture simulator
Outcomes
Primary Outcomes
recovery time
Time Frame: after 7 days of medication
The recovery time will be observed. Recovery means that the main signs and symptoms score is zero, and body temperature is below 37.3 ℃ maintaining for at least 24 hours.
recovery rate
Time Frame: after 7 days of medication
The recovery rate will be observed. Recovery means that the main signs and symptoms score is zero, and body temperature is below 37.3 ℃ maintaining for at least 24 hours.
antibiotic dosage
Time Frame: after 7 days of medication
The dosage of antibiotic will be observed.
antibiotic duration
Time Frame: after 7 days of medication
The duration of antibiotic will be observed.
Secondary Outcomes
- the vanish rate of single symptom/physical sign(after 7 days of medication)
- the ratio of WBC recovery(after 7 days of medication)
- the time of fever relieving(after 7 days of medication)